Parkinson’s and alpha-synuclein
What is alpha-synuclein?
Alpha-synuclein is a protein that is extremely abundant in our brains, making up around 1% of all the proteins floating around in each nerve cell or neuron (the main types of cell in the brain). Proteins make up most of the biological pathways that are going on inside each neuron, and allow our brains to work. In order for each protein to function properly, they must be manufactured correctly.
In healthy neurons, correctly constructed alpha-synuclein is typically found just inside the surface of the neuron membrane as well as in the tips of the branches extending out from the neurons – in structures called presynaptic terminals which are critical to passing the chemical messages between each neuron.
Why is alpha-synuclein relevant to Parkinson’s?
Five genetic mutations in the alpha-synuclein gene have been identified as an associated increased risk of Parkinson’s and these account for 10-20% of people affected by Parkinson’s. So, from a genetic perspective, alpha-synuclein is associated with Parkinson’s; but it is also associated at a protein level.
In the brains of many people with Parkinson’s, some alpha-synuclein protein has been found to be folded in a disordered way. These incorrectly constructed versions of alpha-synuclein clump together in aggregates that are called ‘Lewy bodies’. Lewy bodies are circular clumps of alpha-synuclein (and other proteins) that are found in the brains of people with Parkinson’s. They are abundant in areas of the brain that have suffered cell loss, such as the region of the brain containing neurons that produce dopamine – the hormone which controls feelings of pleasure, satisfaction and motivation; also movement, memory, mood, sleep, learning, concentration, and other body functions.
Alpha-synuclein and Lewy Body forms
We don’t know what causes Lewy bodies to form but there is a lot of evidence supporting the idea that alpha-synuclein is passed between neurons. Once inside, the alpha-synuclein ‘seeds’ the formation of new Lewy bodies inside the next neuron, and this is how the disease is believed to progress.
Can we stop alpha-synuclein clumping, and Lewy bodies from developing and spreading?
This is a very interesting question and one which is being asked and investigated by researchers around the world.
One area of research is that of vaccines that target alpha-synuclein; the idea is that these vaccines will capture and remove the alpha-synuclein being passed between cells and thus stop or at least slow down Parkinson’s progression.
Other areas of research are focused on medicines that inhibit the formation of alpha-synuclein clumps.
An area of research Cure Parkinson’s is involved in is that of the medicine, ambroxol, which has shown to improve the waste clearance from cells, including the mis-folded alpha-synuclein.
More information about alpha-synuclein
Tackling toxic alpha-synuclein Inhibikase makes a case for c-Abl Clinical results from Enterin trialParkinson’s and dementia: improving cognitive measures to enable better treatments
Recently, several international Parkinson’s and Dementia with Lewy Bodies (DLB) advocacy organizations, including Cure Parkinson’s, held a roundtable to discuss the development of better tools for measuring cognitive changes…
Alpha-synuclein or Tau in Parkinson’s?
The build-up of a protein called alpha-synuclein has been considered one of the hallmarks of Parkinson’s. Recently, however, a group of scientists have called into question the ‘bad guy’…
A Review of Our 2023 Preclinical Projects
In 2023, Cure Parkinson’s has funded five new preclinical projects. These preclinical projects address a wide range of ‘targets’ to understand which drugs and which targets should be further…
Our first pipeline project of research
Our first project from our Research Pipeline Acceleration Programme is now underway. Professor Michael Schwarzchild is investigating evidence needed to determine if three iLCT-evaluated compounds are ready to progress…
A biomarker for Parkinson’s?
New research from an international consortium led by the Michael J Fox Foundation has highlighted a potential biological biomarker for Parkinson’s.
Webinar: Clinical trials targeting alpha-synuclein
The latest instalment of this quarterly webinar series discussed clinical trials targeting alpha-synuclein, with Edinburgh University’s Professor Tilo Kunath as chair.
Phase 1a trial findings of iLCT prioritised drug, Anle138b
The findings of the phase 1a clinical trial of Anle138b have been published. Anle138b is a new drug that targets the build-up of alpha synuclein, a protein that clumps…
The lonafarnib pre-clinical study
This research led by Professor Joe Mazzulli, will, it is hoped, give us a better understanding of how lonafarnib can reduce the build-up of the toxic protein alpha-synuclein which…
Tackling toxic alpha-synuclein
Three major lines of clinical investigation are currently underway to determine if stopping the clustering of alpha-synuclein in Parkinson’s can help to slow down the progression of the disease.
The Anle138b Trial
This clinical trial is testing a small molecule called Anle138b to assess its potential to inhibit alpha-synuclein masses accumulating. In Parkinson’s, alpha-synuclein, which is abundant in nerve cells, begins clumping together (or aggregating) and…